Value of 1.0-M gadolinium chelates: Review of preclinical and clinical data on gadobutrol

European Radiology

Volumn 12, Issue 6, 2002, Pages 1550-1556

  Tombach, Bernd ^a   Heindel, Walter ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Contrast media; Gadobutrol; Gd chelate; Magnetic resonance

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM CHELATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERIC ACID; GADOTERIDOL; CONTRAST MEDIUM; DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND;

BRAIN PERFUSION; BRAIN SCINTISCANNING; CHRONIC DISEASE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DATA ANALYSIS; DIAGNOSTIC VALUE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; HEMODIALYSIS; HUMAN; KIDNEY DYSFUNCTION; MAGNETIC RESONANCE ANGIOGRAPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; ANIMAL; BRAIN TUMOR; COMPARATIVE STUDY; SAFETY;

ANIMALS; BRAIN NEOPLASMS; CONTRAST MEDIA; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; ORGANOMETALLIC COMPOUNDS; SAFETY;

EID: 0036594278     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-001-1242-9     Document Type: Review

References (25)

1. Knopp MV, Tengg-Kobligk H von, Floemer F, Schoenberg SO (1999) Contrast agents for MRA: future directions. J Magn Reson Imaging 10:314-316
2. Vogler H, Platzek J, Schuhmann-Giampieri G, Frenzel T, Weinmann HJ, Radüchel B, Press WR (1995) Preclinical evaluation of gadobutrol: a new, neutral, extracellular contrast agent for magnetic resonance imaging. Eur J Radiol 21:1-10
3. Staks T, Schumann-Giampieri G, Frenzel T, Weinmann HJ, Lange L, Platzek J (1994) Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol 29:709-715
4. Mühler A (1995) Assessment of myocardial perfusion using contrast-enhanced MR imaging: current status and future developments. MAGMA 3:21-33
5. Weinmann HJ, Platzek J, Radüchel B, Schumann-Giampieri G, Vogler H (1993) A new macrocyclic gadolinium chelate as a contrast agent for MRI. Eur Radiol 3 (Suppl):126
6. Tweedle MF (1992) Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol (Suppl 1):2-6
7. Tweedle MF (1997) The ProHance story: the making of a novel MRI contrast agent. Eur Radiol 7 (Suppl 5):225-230
8. Bousquet JC, Saini S, Stark DD, Hahn PF, Nigam M, Wittenberg J, Ferrucci JT Jr (1988) Gd-DOTA: characterization of a new paramagnetic complex. Radiology 166:693-698
9. Tombach B, Bremer C, Reimer P, Kisters K, Schaefer RM, Geens V, Heindel W (2001) Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study. Radiology 218:651-657
10. Tombach B, Bremer C, Reimer P, Schaefer RM, Ebert W, Geens V, Heindel W (2000) Pharmacokinetics of 1 M gadobutrol in patients with chronic renal failure. Invest Radiol 35:35-40
11. Tombach B, Bremer C, Reimer P, Matzkies F, Schaefer RM, Ebert W, Geens V, Eisele J, Heindel W (2002) Using a highly concentrated Gadobutrol as an MR contrast agent in patients also requiring hemodialysis: safety and dialysability. AJR Am J Roentgenol 178:105-109
12. Østergaard L, Sorensen AG, Kwong KK, Weisskopf RM, Gyldensted C, Rosen BR (1996) High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. II. Experimental design and preliminary results. Magn Reson Med 36:726-736
13. Rosen BR, Belliveau JB, Chien D (1989) Perfusion imaging by nuclear magnetic resonance. Magn Res Q 5:263-281
14. Rosen B, Belliveau J, Vevea J, Brady T (1990) Perfusion imaging with NMR contrast agents. Magn Reson Med 14:249-266
15. Boxerman JL, Hamberg LM, Rosen BR, Weisskopf RM (1995) MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 34:555-566
16. Mühler A, Weinmann HJ (1995) Arterial concentrations following intravenous bolus injection of gadobutrol. Comparison of 0.5 and 1.0 M stock solutions. Proc Intl Soc Mag Reson Med 3:1128
17. Heiland S, Benner T, Reith W, Forsting M, Sartor K ( 1997) Perfusion-weighted MRI using gadobutrol as a contrast agent in a rat stroke model. J Magn Reson Imaging 7:1109-1115
18. Tombach B, Reimer P, Prümer B, Allkemper T, Bremer C, Mühler A, Heindel W (1999) Does a higher concentration of gadolinium chelates improve first-pass cardiac signal changes? J Magn Reson Imaging 10:806-812
19. Kawai J, Takahashi M, Kato N, Takashima K, Miyazawa T (1999) Comparison of a 1.0 molar and a 0.5 molar formulation of gadobutrol in dynamic MR imaging of the liver in rats with hepatocellular carcinoma. Magn Reson Imaging 17:91-97
20. Dong Q, Hurst DR, Weinmann HJ, Chenevert TL, Londy FJ, Prince MR (1998) Magnetic resonance angiography with gadomer 17. An animal study original investigation. Invest Radiol 33:699-708
21. Lemke AJ, Sander B, Balzer T, Geens V, Hosten N, Felix R (1997) Sicherheit und Nutzen von Gadobutrol bei Patienten mit zerebralen Tumoren (Phase-III-Studie). Fortschr Röntgenstr 167:591-598
22. Vogl TJ, Friebe CE, Balzer T, Mack MG, Steiner S, Schedel H, Pegios W, Lanksch W, Banzer D, Felix R (1995) Diagnosis of cerebral metastasis with standard dose gadobutrol vs. high dose protocol. Intraindividual evaluation of a phase II high dose study. Radiologe 35:508-516
23. Knauth M, Forsting M, Hartmann M, Heiland S, Balzer T, Sartor K (1996) MR enhancement of brain lesions: increased contrast dose compared with magnetization transfer. Am J Neuroradiol 17:1853-1859
24. Benner T, Reimer P, Erb G, Schuierer G, Heiland S, Fischer C, Geens V, Sartor K, Forsting M (2000) Cerebral MR perfusion imaging: first clinical application of a 1 molar gadolinium chelate (Gadovist 1.0) in a double-blinded randomized dose finding study. J Magn Reson Imaging 12:371-380
25. Benner T, Tombach B, Synnott JP, Reimer P, Geens V, Ostergaard L, Sorensen AG (2000) Human cerebral blood flow maps improve with higher concentration of contrast agents. Proc Int Soc Magn Reson Med:2024